LGR5
ENSG00000139292
Target class
Unclassified protein
Chromosome
12
- Chemical probe available
- No
- Target name
- LGR5
- Gene name
- Leucine rich repeat containing G protein-coupled receptor 5
- Gene symbol
- LGR5
- Protein name
- Leucine-rich repeat-containing G-protein coupled receptor 5 (G-protein coupled receptor 49) (G-protein coupled receptor 67) (G-protein coupled receptor HG38)
- HG38
- FEX
- GPR67
- GPR49
- Gene biotype
- Protein coding
- Gene family
- G protein-coupled receptors, Class A orphans
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 23
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 15.33
- Tissue specificity (Gini)
- 0.655
- Tissue specificity (tau)
- 0.899
- KEGG gene identifiers
- hsa:8549
- Reactome pathways
- R-HSA-4641263
- Protein interaction confidence
- 0.834542
- Protein interaction partners
- 24
- End position
- 71586310
- Start position
- 71439797
- Chromosome
- 12
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein. Golgi apparatus, trans-Golgi network membrane
- Multi-pass membrane protein. Note=Rapidly and constitutively internalized to the trans-Golgi network at steady state. Internalization to the trans-Golgi network may be the result of phosphorylation at Ser-861 and Ser-864
- however, the phosphorylation event has not been proven (PubMed:23439653). .
- Basal body
- Centrosome
- Nucleoplasm
- Primary cilium transition zone
- Vesicles
Publication evidence
- PubMed 23439653
- Tissue specificity (tau)
- 0.899396
- Expression inequality (Gini)
- 0.654776
Expression in transcripts per million
- Muscle - Skeletal
- 15.33
- Brain - Spinal cord (cervical c-1)
- 14.81
- Nerve - Tibial
- 7.22
- Small Intestine - Terminal Ileum
- 5.88
- Skin - Sun Exposed (Lower leg)
- 4.33
Expression in transcripts per million
- Muscle - Skeletal15.33
- Brain - Spinal cord (cervical c-1)14.81
- Nerve - Tibial7.22
- Small Intestine - Terminal Ileum5.88
- Skin - Sun Exposed (Lower leg)4.33
- Artery - Aorta3.96
- Fallopian Tube3.73
- Brain - Substantia nigra3.66
- Brain - Hippocampus2.72
- Minor Salivary Gland2.54
- Skin - Not Sun Exposed (Suprapubic)2.42
- Artery - Tibial2.38
- Brain - Hypothalamus2.22
- Adipose - Subcutaneous1.89
- Adrenal Gland1.78
- Colon - Transverse1.77
- Ovary1.48
- Brain - Amygdala1.47
- Breast - Mammary Tissue1.3
- Brain - Caudate (basal ganglia)1.3
- Lung1.18
- Brain - Putamen (basal ganglia)1.09
- Brain - Cortex1.01
- Brain - Frontal Cortex (BA9)0.95
- Artery - Coronary0.91
And 29 more, listed on the interactive page.
- GO:0007186
- GO:0090263
- GO:0005886
- GO:0032588
- GO:0004888
- GO:0004930
- GO:0005515
Related records
Trials (6)
- A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
- A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
- A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
- Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
- Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer